time to progression (TTP) for chemotherapy naive subjects with advanced hepatocellular carcinoma (HCC) time to progression, up to 2 years [clinicaltrials_resource:797cb798868b7e1be405bf9b3a0a02ea]
Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
time to progression (TTP) for chemotherapy naive subjects with advanced hepatocellular carcinoma (HCC) time to progression, up to 2 years [clinicaltrials_resource:797cb798868b7e1be405bf9b3a0a02ea]
Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
Bio2RDF identifier
797cb798868b7e1be405bf9b3a0a02ea
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:797cb798868b7e1be405bf9b3a0a02ea
measure [clinicaltrials_vocabulary:measure]
time to progression (TTP) for ...... hepatocellular carcinoma (HCC)
time frame [clinicaltrials_vocabulary:time-frame]
time to progression, up to 2 years
description
Combination of CS-1008 and sor ...... e treatment until progression.
identifier
clinicaltrials_resource:797cb798868b7e1be405bf9b3a0a02ea
title
time to progression (TTP) for ...... to progression, up to 2 years
@en
type
label
time to progression (TTP) for ...... cb798868b7e1be405bf9b3a0a02ea]
@en